| General Information | |
|---|---|
| ZINC ID | ZINC000064539459 |
| Molecular Weight (Da) | 410 |
| SMILES | COc1cccc2c(C(=O)N3CCN4CCC[C@@]4(C)C3)cn(CC3CCCCC3)c12 |
| Molecular Formula | C25N3O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 118.402 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| LogP | 4.34 |
| Activity (Ki) in nM | 1258.93 |
| Polar Surface Area (PSA) | 37.71 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.66651362 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 9 |
| Fraction csp3 | 0.64 |
| Ilogp | 4.27 |
| Xlogp3 | 4.29 |
| Wlogp | 3.78 |
| Mlogp | 3.19 |
| Silicos-it log p | 3.67 |
| Consensus log p | 3.84 |
| Esol log s | -4.97 |
| Esol solubility (mg/ml) | 0.00435 |
| Esol solubility (mol/l) | 0.0000106 |
| Esol class | Moderately |
| Ali log s | -4.79 |
| Ali solubility (mg/ml) | 0.00657 |
| Ali solubility (mol/l) | 0.000016 |
| Ali class | Moderately |
| Silicos-it logsw | -5.28 |
| Silicos-it solubility (mg/ml) | 0.00216 |
| Silicos-it solubility (mol/l) | 0.00000528 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.75 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.97 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.508 |
| Logd | 3.983 |
| Logp | 5.081 |
| F (20%) | 0.94 |
| F (30%) | 0.1 |
| Mdck | - |
| Ppb | 81.20% |
| Vdss | 1.47 |
| Fu | 9.41% |
| Cyp1a2-inh | 0.107 |
| Cyp1a2-sub | 0.947 |
| Cyp2c19-inh | 0.628 |
| Cyp2c19-sub | 0.947 |
| Cl | 5.067 |
| T12 | 0.021 |
| H-ht | 0.836 |
| Dili | 0.777 |
| Roa | 0.618 |
| Fdamdd | 0.557 |
| Skinsen | 0.318 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.958 |
| Bcf | 1.165 |
| Igc50 | 3.725 |
| Lc50 | 4.259 |
| Lc50dm | 4.454 |
| Nr-ar | 0.241 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.396 |
| Nr-aromatase | 0.505 |
| Nr-er | 0.156 |
| Nr-er-lbd | 0.013 |
| Nr-ppar-gamma | 0.006 |
| Sr-are | 0.652 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.631 |
| Sr-mmp | 0.348 |
| Sr-p53 | 0.026 |
| Vol | 435.562 |
| Dense | 0.94 |
| Flex | 0.185 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.744 |
| Synth | 3.171 |
| Fsp3 | 0.64 |
| Mce-18 | 98.122 |
| Natural product-likeness | -0.552 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |